Liver Fat Equipment & Supplies
11 equipment items found
Manufactured by:Altimmune Inc. based inGaithersburg, MARYLAND (USA)
A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty ...
by:CohBar, Inc. based inMenlo Park, CALIFORNIA (USA)
We believe CB4211 offers a differentiated approach to treating nonalcoholic steatohepatitis (NASH) and obesity. Is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP) that plays a key role in regulating metabolism. Has resulted in significant impacts on NASH and obesity in multiple preclinical models. Has been shown in a clinical study to significantly ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Ambrisentan is a selective ET type A receptor (ETAR) ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic ...
Manufactured by:BioSupply Ltd. based inShipley, UNITED KINGDOM
Human adiponectin ELISA kit is a reliable quantitative procedure for measuring adiponectin in human serum or heparin plasma samples. This assay has a minimum sensitivity detection limit of 0.6 ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-300-IV is being developed for the treatment of diabetic complications, including diabetic kidney disease known as diabetic ...